3-methyl-4-methylthioacetophenone | 32467-07-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-methyl-4-methylthioacetophenone
• 英文别名: 1-[3-Methyl-4-(methylsulfanyl)phenyl]ethan-1-one；1-(3-methyl-4-methylsulfanylphenyl)ethanone
• CAS: 32467-07-5
• 化学式: C₁₀H₁₂OS
• 分子量: 180.271
• InChiKey: UJSIWMXCIHGKDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methyl-4-methylthioacetophenone 在 Oxone 、 sodium hydride 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 27.0h， 生成 5-[5-(3-methyl-4-methylsulfonylphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1,1-dioxo-2,3-dihydrobenzo[d]isothiazole
  参考文献：
  名称：

  Pal, Manojit; Veeramaneni, Venugopal Rao; Kumar, Sanjeev, Journal of the Indian Chemical Society, 2003, vol. 80, # 12, p. 1095 - 1101

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲苄基硫醇 、 乙酰氯 在 aluminium chloride 作用下， 以 氯仿 为溶剂， 以80%的产率得到3-methyl-4-methylthioacetophenone
  参考文献：
  名称：

  1-(4-Alkylthiopheny)-2-substituted amino-alcohols and their salts

  摘要：

  根据发明，新的氨基醇可由以下式表示：其中：R.sub.1代表RS、RSO或RSO.sub.2基团，其中R为直链或支链烷基(C.sub.1 -C.sub.10)、乙酰基团或氢原子；R.sub.2和R.sub.3，可能相同也可能不同，代表卤素原子或烷基(C.sub.1 -C.sub.3)、氨基、烷基氨基(C.sub.1 -C.sub.4)、酰胺基、硝基、羧基、羧酸烷氧基、三氟甲基、烷氧基(C.sub.1 -C.sub.4)或烷硫基(C.sub.1 -C.sub.4)基团；R.sub.4代表氢原子或含有1-4个碳原子的直链或支链烷基基团；R.sub.5和R.sub.6，可能相同也可能不同，代表氢原子、取代或非取代的直链或支链烷基(C.sub.1 -C.sub.16)基团、环烷基(C.sub.5 -C.sub.6)基团、炔基(C.sub.3 -C.sub.4)基团、烯基(C.sub.3 -C.sub.4)基团或哌啶、吗啉、吡啶或吡啶咪唑等异环的基团，R.sub.5和R.sub.6也可以与相邻的氮原子形成取代或非取代的杂环基团；其中R.sub.2和R.sub.3中的一个可以是氢原子，或者同时R为RS中的较低烷基(C.sub.1 -C.sub.3)基团时，R.sub.4和R.sub.5为氢原子，R.sub.6为异丙基或叔丁基基团；或者同时R为RSO.sub.2中的甲基基团时，R.sub.4和R.sub.5为氢原子，R.sub.6为异丙基基团。当R.sub.5和R.sub.6代表烷基时，后者可以被氨基、烷基氨基、羟基、烷氧基、苯氧基、取代苯氧基、苯基、取代苯基基团或哌啶啉或吗啉等异环所取代。

  公开号：

  US03954871A1

文献信息

• 1-(4-Alkylthiopheny)-2-substituted amino-alcohols and their salts
  申请人：Continental Pharma

  公开号：US03954871A1

  公开（公告）日：1976-05-04

  The new amino-alcohols according to the invention are represented by the formula ##SPC1## Wherein: R.sub.1 represents a RS, RSO or RSO.sub.2 group in which R is a linear or branched alkyl group (C.sub.1 -C.sub.10), an acetyl radical or hydrogen; R.sub.2 and R.sub.3, which may be identical or different, represent a halogen atom or an alkyl (C.sub.1 -C.sub.3), amino, alkylamino (C.sub.1 -C.sub.4), acylamino, nitro, carboxy, carbalkoxy, trifluoromethyl, alkoxy (C.sub.1 -C.sub.4) or alkylthio (C.sub.1 -C.sub.4) radical; R.sub.4 represents hydrogen or a linear or branched alkyl radical containing 1 - 4 carbon atoms; R.sub.5 and R.sub.6, which may be identical or different, represent hydrogen, a substituted or not, linear or branched alkyl (C.sub.1 -C.sub.16) radical, a cycloalkyl (C.sub.5 -C.sub.6) radical, an alkynyl (C.sub.3 -C.sub.4) radical, an alkenyl (C.sub.3 -C.sub.4) radical or a heterocycle of the kind piperidine, morpholine, pyridine or pyridimine, R.sub.5 and R.sub.6 can also form with adjacent nitrogen atom a heterocyclic radical, substituted or not; one of said R.sub.2 and R.sub.3 can be a hydrogen atom or can be both a hydrogen atom provided that simultaneously R is a lower alkyl (C.sub.1 -C.sub.3) radical in the group RS, R.sub.4 and R.sub.5 are hydrogen atoms and R.sub.6 is an isopropyl or t-butyl radical or if simultaneously R is a methyl radical in the group RSO.sub.2, R.sub.4 and R.sub.5 are hydrogen atoms and R.sub.6 is an isopropyl radical. When R.sub.5 and R.sub.6 represent an alkyl, the latter can be substituted by amino, alkylamino, hydroxy, alkoxy, phenoxy, substituted phenoxy, phenyl, substituted phenyl radical or a heterocycle such as piperidino or morpholino.

  根据发明，新的氨基醇可由以下式表示：其中：R.sub.1代表RS、RSO或RSO.sub.2基团，其中R为直链或支链烷基(C.sub.1 -C.sub.10)、乙酰基团或氢原子；R.sub.2和R.sub.3，可能相同也可能不同，代表卤素原子或烷基(C.sub.1 -C.sub.3)、氨基、烷基氨基(C.sub.1 -C.sub.4)、酰胺基、硝基、羧基、羧酸烷氧基、三氟甲基、烷氧基(C.sub.1 -C.sub.4)或烷硫基(C.sub.1 -C.sub.4)基团；R.sub.4代表氢原子或含有1-4个碳原子的直链或支链烷基基团；R.sub.5和R.sub.6，可能相同也可能不同，代表氢原子、取代或非取代的直链或支链烷基(C.sub.1 -C.sub.16)基团、环烷基(C.sub.5 -C.sub.6)基团、炔基(C.sub.3 -C.sub.4)基团、烯基(C.sub.3 -C.sub.4)基团或哌啶、吗啉、吡啶或吡啶咪唑等异环的基团，R.sub.5和R.sub.6也可以与相邻的氮原子形成取代或非取代的杂环基团；其中R.sub.2和R.sub.3中的一个可以是氢原子，或者同时R为RS中的较低烷基(C.sub.1 -C.sub.3)基团时，R.sub.4和R.sub.5为氢原子，R.sub.6为异丙基或叔丁基基团；或者同时R为RSO.sub.2中的甲基基团时，R.sub.4和R.sub.5为氢原子，R.sub.6为异丙基基团。当R.sub.5和R.sub.6代表烷基时，后者可以被氨基、烷基氨基、羟基、烷氧基、苯氧基、取代苯氧基、苯基、取代苯基基团或哌啶啉或吗啉等异环所取代。
• Triazine derivatives, a process for preparing the derivatives, and
  申请人：Idemitsu Kosan Company Limited

  公开号：US04680054A1

  公开（公告）日：1987-07-14

  A triazine derivative represented by the general formula: ##STR1## wherein R.sup.1 and R.sup.2 are each an alkyl group having 1 to 4 carbon atoms, and X.sup.1 and X.sup.2 are each a halogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxyl group having 1 to 4 carbon atoms, or an alkylthio group having 1 to 4 carbon atoms. This invention also provides a process for efficiently preparing said triazine derivative and a herbicide containing said triazine derivative as effective component.

  一种由以下通式表示的三嗪衍生物：##STR1## 其中R.sup.1和R.sup.2分别是具有1到4个碳原子的烷基基团，X.sup.1和X.sup.2分别是卤素原子、具有1到4个碳原子的烷基基团、具有1到4个碳原子的烷氧基基团或具有1到4个碳原子的烷基硫基团。本发明还提供了一种有效制备所述三嗪衍生物的方法和含有所述三嗪衍生物作为有效成分的除草剂。
• PYRAZOLONE DERIVATIVES AS NITROXYL DONORS
  申请人：Cardioxyl Pharmaceuticals, Inc.

  公开号：US20150344437A1

  公开（公告）日：2015-12-03

  The disclosed subject matter provides pyrazolone derivative compounds, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.

  所披露的主题提供了吡唑酮衍生物化合物，包含这些化合物的药物组合物，包含这些化合物的工具箱，以及使用这些化合物或药物组合物的方法。具体而言，所披露的主题提供了使用这些化合物或药物组合物治疗心力衰竭的方法。
• Triazine Derivatives, a process for preparing the derivatives, and herbicides containing the derivatives as the effective component
  申请人：IDEMITSU KOSAN COMPANY LIMITED

  公开号：EP0191496A2

  公开（公告）日：1986-08-20

  A triazine derivative represented by the general formula: wherein R1 and R2 are each an alkyl group having 1 to 4 carbon atoms, and X1 and X2 are each a halogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxyl group having 1 to 4 carbon atoms, or an alkylthio group having 1 to 4 carbon atoms. This invention also provides a process for efficiently preparing said triazine derivative and a herbicide containing said triazine derivative as effective component.

  由通式代表的三嗪衍生物： 其中 R1 和 R2 分别为具有 1 至 4 个碳原子的烷基，X1 和 X2 分别为卤素原子、具有 1 至 4 个碳原子的烷基、具有 1 至 4 个碳原子的烷氧基或具有 1 至 4 个碳原子的烷硫基。 本发明还提供了一种高效制备所述三嗪衍生物和含有所述三嗪衍生物作为有效成分的除草剂的工艺。
• Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors:  Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1<i>H</i>-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)
  作者：Thomas D. Penning、John J. Talley、Stephen R. Bertenshaw、Jeffery S. Carter、Paul W. Collins、Stephen Docter、Matthew J. Graneto、Len F. Lee、James W. Malecha、Julie M. Miyashiro、Roland S. Rogers、D. J. Rogier、Stella S. Yu、Gary D. Anderson、Earl G. Burton、J. Nita Cogburn、Susan A. Gregory、Carol M. Koboldt、William E. Perkins、Karen Seibert、Amy W. Veenhuizen、Yan Y. Zhang、Peter C. Isakson

  DOI：10.1021/jm960803q

  日期：1997.4.1

  A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC-236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of ii (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.